CN106636105A - Aptamer C203 of staphylococcal enterotoxin C2, screening method and application thereof - Google Patents

Aptamer C203 of staphylococcal enterotoxin C2, screening method and application thereof Download PDF

Info

Publication number
CN106636105A
CN106636105A CN201611170849.9A CN201611170849A CN106636105A CN 106636105 A CN106636105 A CN 106636105A CN 201611170849 A CN201611170849 A CN 201611170849A CN 106636105 A CN106636105 A CN 106636105A
Authority
CN
China
Prior art keywords
staphylococcus aureus
aptamer
aureus enterotoxin
enterotoxin
ssdna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201611170849.9A
Other languages
Chinese (zh)
Other versions
CN106636105B (en
Inventor
王开宇
兰小鹏
廖剑
洪笑迁
闫慧慧
杨湘越
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuzhou General Hospital of Nanjing Military Command of PLA
Original Assignee
Fuzhou General Hospital of Nanjing Military Command of PLA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuzhou General Hospital of Nanjing Military Command of PLA filed Critical Fuzhou General Hospital of Nanjing Military Command of PLA
Priority to CN201611170849.9A priority Critical patent/CN106636105B/en
Publication of CN106636105A publication Critical patent/CN106636105A/en
Application granted granted Critical
Publication of CN106636105B publication Critical patent/CN106636105B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1048SELEX
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • G01N33/56938Staphylococcus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/16Aptamers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to an aptamer C203 of staphylococcal enterotoxin C2, a screening method and an application thereof. The sequence of the aptamer C203 is AGGGCCGAGCTCACTTGTCAGGTCGCCTCTTGCGCGGCGCACGGGCGGAAACGCCGCCGGCACAATTGTGC; the screening method of the aptamer C203 comprises the steps that the SELEX screening technology in vitro based on the aptamer uses carboxyl magnetic beads as a solid phase media, the staphylococcal enterotoxin C2 is used as a target, by the staphylococcal enterotoxin C2 magnetic beads, the aptamer specifically binding with the staphylococcal enterotoxin C2 is screened and obtained from the ssDNA library; the aptamer C203 is capable of binding with the staphylococcal enterotoxin C2 in a highly affiliative and highly specific mode.

Description

The aptamer C203 of staphylococcus aureus enterotoxin C 2 and its screening technique and Using
Technical field
The present invention relates to the aptamer C203 and its screening technique of a kind of staphylococcus aureus enterotoxin C 2 and should With.
Background technology
Staphylococcus aureus enterotoxin is the exotoxin with superantigen activity secreted by staphylococcus aureus.Gold Staphylococcus aureus enterotoxin can be processed without antigen presenting cell, directly with the nonrestrictive combination of MHC class Ⅱmolecules, be formed Compound combined with the β chain V areas of t lymphocyte antigen receptor, a large amount of activated T lymphocytes so as to activate, breed, and release The inflammatory cytokine of amplification quantity causes strong immune response, ultimately results in the infringement of uncontrolled inflammation and multiple organ, causes poison The diseases such as element shock.It is heat-resisting and only need the very little dosage can further, since Staphylococcus aureus enterotoxin is relatively resistant to digestion Cause t cell response, Staphylococcus aureus enterotoxin is also by the super antigen medicine as oncotherapy.
Staphylococcus aureus enterotoxin has multiple serotypes, is respectively A types, Type B, C1 types, C2 types, C3 types, D types, E Type, G types, H types, I types, M types, N-type, the O-shaped and type toxin of toxic shock syndrome 1, the type toxin of toxic shock syndrome 2 etc., its Middle staphylococcus aureus enterotoxin C 2 is not only relevant with staphylococcus aureus infections relating, while being also Staphylococcus aureus Most super antigen medicines is applied in bacterium enterotoxin.
Detection staphylococcus aureus enterotoxin C 2 mainly adopt immunological method, including precipitation reaction, agglutinating reaction, ELISA, solid-phase RIA, biology sensor etc., these methods use the knowledge that antibody is detected as staphylococcus aureus enterotoxin C 2 Other element, and the preparation of antibody has cycle weak points such as long, complex steps, cost height.In recent years, detecting golden yellow Portugal Grape coccus Enteromycin C 2 gene is very fast for the molecular biology method development of target, but PCR equimolecular biological methods are still suffered from The technical barriers such as false positive, false negative.Therefore, develop with more high sensitivity, economy, easy staphylococcus aureus intestines poison Plain C2 new detecting techniques, it is all significant for Food Hygiene Surveillance, the diagnosis and treatment of clinical infection of staphylococcus aureus etc..
The Endotoxin Shock that treatment staphylococcus aureus enterotoxin C 2 causes, it is clinical to prop up to the ill frequently with anti-inflammatory, fluid infusion etc. Hold therapy.Current research finds that the superantigen activity of suppression staphylococcus aureus enterotoxin C 2 blocks inflammation in the starting stage The generation of cascade reaction, is the available strategy for treating staphylococcus aureus enterotoxin C 2 relevant disease.Based on this strategy, develop Various polypeptide drugs, antibody drug, vaccine etc., it has also become staphylococcus aureus enterotoxin C 2 biotechnology new drug research Focus.
The acquisition of staphylococcus aureus enterotoxin C 2 super antigen medicine, frequently with the method for gene cloning, by golden yellow Aureus enterotoxin C 2 gene fragment clone in expression in escherichia coli and is purified into prokaryotic expression carrier.But this side Frequently with ion-exchange process or the affinity purification method of tape label, the former adsorbs selection poor specificity to purification step in method, after Person's reagent cost is higher.
Aptamers are otherwise known as " synthetic antibody ", " chemical antibody ", and its chemical nature is a single-stranded oligonucleotide molecule (ssDNA or RNA) is folded into specific three dimensional structure and is combined with target substance high-affinity and high specific.Aptamers are passed through Phyletic evolution technology (the Systematic evolution of ligands by of index concentration part Exponentialenrichment, SELEX) in-vitro screening process.Aptamer have high-affinity, high specific, can External synthesis, can by modification change its function and pharmacokinetic properties, non-immunogenicity, it is economical the features such as.Based on above-mentioned The aptamer medicine of advantage exploitation can specific inhibition target function;Using aptamer as recognition component, can also open Send out easy, accurately new detecting technique and efficient economy affinity purification system.Therefore, high specific is filtered out, height is affine Power has important scientific research, clinical and market value with reference to the aptamer of staphylococcus aureus enterotoxin C 2.
The content of the invention
It is an object of the invention to provide a kind of Staphylococcus aureus enterotoxin with high specific and high-affinity The aptamer C203 of C2 and its screening technique and application.
The purpose of the present invention is achieved through the following technical solutions:A kind of nucleic acid adaptation of staphylococcus aureus enterotoxin C 2 Body C203, its sequence is as follows:
AGGGCCGAGCTCACTTGTCAGGTCGCCTCTTGCGCGGCGC 40
ACGGGCGGAAACGCCGCCGGCACAATTGTGC 71
The screening technique of the aptamer C203 of described staphylococcus aureus enterotoxin C 2, based on aptamer External SELEX triage techniqueses, by the use of carboxyl magnetic bead as solid-phase media, with staphylococcus aureus enterotoxin C 2 as target, Screened from ssDNA libraries by staphylococcus aureus enterotoxin C 2 magnetic bead and obtain special with staphylococcus aureus enterotoxin C 2 The aptamer that the opposite sex is combined.
The application of the aptamer C203 of described staphylococcus aureus enterotoxin C 2, it is golden yellow separating, purifying Application in aureus enterotoxin C 2.
The application of the aptamer C203 of described staphylococcus aureus enterotoxin C 2, in the golden yellow Portugal of analysis detection Non-diseases methods for diagnosis and treatment application in grape coccus Enteromycin C 2.
The application of the aptamer C203 of described staphylococcus aureus enterotoxin C 2, in staphylococcus aureus intestines Toxin C2 is the application in the targeted therapy of effector molecule.
The application of the aptamer C203 of described staphylococcus aureus enterotoxin C 2, in treatment Staphylococcus aureus Application in bacterium infection and in treatment staphylococcus aureus enterotoxin C 2 causes related syndrome.
For than prior art, it is an advantage of the current invention that:
1. aptamer C203 is non-toxic, and molecular weight is little, good penetrability, it is easy to synthesis and mark.
2. the synthesis cost of aptamer C203 compared with Antibody preparation low cost, and cycle is short, favorable reproducibility.
3. aptamer C203 can high-affinity, combined with staphylococcus aureus enterotoxin C 2 with high specificity, Dissociation constant is 3.05 ± 0.89nM, and it does not have identification function to other homologous proteins.
4. aptamer C203 staphylococcus aureus enterotoxin C 2 separation, purifying, staphylococcus aureus The related food safety detection of Enteromycin C 2, the diagnosis and treatment of staphylococcus aureus enterotoxin C 2 relevant disease are golden yellow The field aspects such as the diagnosis and treatment of staphy lococcus infection, the targeted therapy of staphylococcus aureus enterotoxin C 2 mediation have wide Wealthy application prospect and important science, society, economic worth.
Description of the drawings
Fig. 1 is the biological information simulation drawing of aptamer C203 secondary structures.
Fig. 2 schemes for the specificity of fluorescence Percentage bound experimental analysis aptamer C203.In fig. 2, abscissa is analysis Albumen, ordinate be fluorescence Percentage bound.
Fig. 3 is the dissociation that fluorescence Percentage bound experimental analysis aptamer C203 combines staphylococcus aureus enterotoxin C 2 Constant draws curve.Dissociation constant (Kd) is 3.05 ± 0.89nM.In figure 3, abscissa is DNA concentration (pM), and ordinate is Fluorescence Percentage bound.
Fig. 4 is that CCK-8 methods determine the PBMC propagation that aptamer C203 is induced staphylococcus aureus enterotoxin C 2 The effect of activity.
Specific embodiment
Present invention is described in detail with reference to Figure of description and embodiment:
A kind of aptamer C203 of staphylococcus aureus enterotoxin C 2, its sequence is as follows:
AGGGCCGAGCTCACTTGTCAGGTCGCCTCTTGCGCGGCGC 40
ACGGGCGGAAACGCCGCCGGCACAATTGTGC 71
The aptamer C203 of described staphylococcus aureus enterotoxin C 2, at 25 DEG C, 100mM Na+, 1mM Mg2+ Under conditions of, its space structure is as follows:
The aptamer C203 of described staphylococcus aureus enterotoxin C 2,5 ' to the aptamer C203 End or 3 ' ends carry out FITC, amino, biotin, digoxin chemical modification.
The aptamer C203 of described staphylococcus aureus enterotoxin C 2, cuts to the aptamer C203 Product obtained by the structure of modification that short or prolongation or number of base are replaced carries out FITC, amino, biotin, digoxin chemistry and repaiies Decorations.
The screening technique of the aptamer C203 of described staphylococcus aureus enterotoxin C 2, based on aptamer External SELEX triage techniqueses, by the use of carboxyl magnetic bead as solid-phase media, with staphylococcus aureus enterotoxin C 2 as target, Screened from ssDNA libraries by staphylococcus aureus enterotoxin C 2 magnetic bead and obtain special with staphylococcus aureus enterotoxin C 2 The aptamer that the opposite sex is combined.
The screening technique of the aptamer C203 of described staphylococcus aureus enterotoxin C 2, it includes following step Suddenly:
(1) preparation in library is screened:Prepare the ssDNA pool shown in following sequence:
5’-AGGGCCGAGCTCACTTGT-N35-CCGCCGGCACAATTGTGC-3’;
(2) staphylococcus aureus enterotoxin C 2 and carboxyl magnetic bead coupling are prepared into staphylococcus aureus enterotoxin C 2 magnetic Pearl;
(3) ssDNA libraries are carried out into hot activation process;
(4) by the staphylococcus aureus enterotoxin C 2 magnetic bead obtained by the ssDNA libraries Jing after step (3) and step (2) It is incubated;
(5) staphylococcus aureus enterotoxin C 2 magnetic bead of the Magnetic Isolation Jing after step (4), washes away staphylococcus aureus Enteromycin C 2 magnetic bead surfaces are uncombined, the ssDNA of weak binding and non-specific binding;Heating staphylococcus aureus enterotoxin C 2 Magnetic bead, collects the ssDNA with the specific binding of staphylococcus aureus enterotoxin C 2 magnetic bead, i.e. ssDNA enriched libraries;
(6) PCR amplifications:SsDNA enriched libraries obtained by step (5) are entered into performing PCR amplification, wherein PCR expands used Primer is:
Primer P1:5’-FAM-AGGGCCGAGCTCACTTGT-3’
Primer P2:5’-Biotin-GCACAATTGTGCCGGCGG-3’;
(7) purifying of PCR primer:PCR primer is purified using small fragment purification kit;By after purification DsDNA is incubated with Streptavidin MagneSphere, after Streptavidin MagneSphere is scrubbed, dsDNA unwinds, is used with reference to dsDNA Magnetic frame is separated, and collects supernatant;Supernatant obtains the secondary ssDNA libraries for next round screening Jing after ethanol precipitation;
(8) Cycle Screening:By the secondary ssDNA libraries of the FAM marks obtained by step (7), as the secondary of next round screening Level library, and the screening process of repeat step (3)~(7).
Embodiment one:The screening of aptamer C203
The screening technique of the aptamer C203 of described staphylococcus aureus enterotoxin C 2, it includes following step Suddenly:
(1) preparation in library is screened:Design two ends FX is 18 nucleotides, middle random areas are 35 nucleosides SsDNA pool (the 5 '-AGGGCCGAGCTCACTTGT-N of acid35- CCGCCGGCACAATTGTGC-3 '), and student on commission's work Bioengineering limited company synthesizes.
(2) staphylococcus aureus enterotoxin C 2 is coupled with carboxyl magnetic bead:The staphylococcus aureus enterotoxin C 2 egg Toxin Technology companies of the U.S. are purchased from vain, and the carboxyl magnetic bead and its coupling reagent are purchased from U.S. Bangs Laboratories companies, the specification that operation is provided with reference to manufacturer;It is golden yellow before and after being coupled by BCA method determination of protein concentration The change of protein concentration in color aureus enterotoxin C 2 solution, be computed magnetic bead couples efficiency for 85%;By golden yellow Portugal Grape coccus Enteromycin C 2 magnetic bead is scattered in PBS, 4 DEG C of preservations.
(3) take 2nmol ssDNA pools be dissolved in 500 μ L select buffer solution (50mM Tris-HCl, 100mM NaCl, 1mM MgCl2, 5mM KCl, pH7.4), then Jing hot activations are processed.Wherein, the method for hot activation process is:95 DEG C of denaturation After 5min, ice bath 10min in ice-water bath is immediately placed on, is subsequently placed at room temperature 10min.
(4) by the staphylococcus aureus enterotoxin C 2 magnetic bead obtained by the ssDNA libraries Jing after step (3) and step (2) Mixing is simultaneously for (staphylococcus aureus enterotoxin C 2 carrying capacity is 100ng) and yeast tRNA (mole is 5 times of ssDNA libraries) In incubation at room temperature 1h.
(5) staphylococcus aureus enterotoxin C 2 magnetic bead of the Magnetic Isolation Jing after step (4), with the selection containing 0.2%BSA Buffer solution washes away the ssDNA of uncombined staphylococcus aureus enterotoxin C 2 magnetic bead surfaces, weak binding and non-specific binding;So Afterwards by staphylococcus aureus enterotoxin C 2 magnetic bead with 200 μ L ddH2O is resuspended, after 100 DEG C of hot bath 5min, is placed in magnetic frame 1-2min, collects supernatant, obtains the ssDNA with the specific binding of staphylococcus aureus enterotoxin C 2 magnetic bead, i.e. ssDNA enrichments Library.
(6) PCR amplifications:SsDNA enriched libraries obtained by step (5) are added in 1mL PCRmix;Vortex oscillation is mixed After even, dispense into performing PCR amplification by the μ L of every pipe 50, amplification condition is:After 94 DEG C of denaturations 5min;94 DEG C of denaturation 30S, 58 DEG C are moved back Fiery 30S, 72 DEG C of extension 30S, 15-25 circulation.
Contain in wherein 1mL PCRmix:The μ L of 10 × PCR buffer solutions 100;The μ L of pfu enzymes 3;dNTP 20μL;Primer P1:5’- FAM-AGGGCCGAGCTCACTTGT-3 ' and primer P2:The each 3 μ L of 5 '-Biotin-GCACAATTGTGCCGGCGG-3 ';It is described to draw The equal student on commission's work bioengineering limited company synthesis of thing P1 and primer P2.
(7) purifying of PCR primer:Two ends indicate respectively the PCR primer of biotin and fluorophor FAM, using small fragment Purification Kit (described small fragment purification kit be purchased from Sheng Gong bioengineering limited company), by after purification DsDNA is incubated 20min with Streptavidin MagneSphere (being purchased from Invitrogen-Dynal companies) at 37 DEG C, uses lavation buffer solution After (5mM Tris-HCl, pH7.5,1M NaCl, 500 μM of EDTA) washing is with reference to the Streptavidin MagneSphere three times of dsDNA, use 50 μ L NaOH solutions (0.1M) are incubated 30min at 37 DEG C makes dsDNA unwind;Separated with magnetic frame, collect supernatant, supernatant Jing second Alcohol precipitation obtains the secondary ssDNA libraries of FAM marks, and is dissolved in selection buffer solution, used as the secondary text of next round screening Storehouse.
(8) screening process carries out altogether 9 wheels.From the beginning of the second wheel, the consumption of secondary library is 50pmol.
Embodiment two:The analysis of aptamer C203 sequences:
(1) after 9 wheel screenings, the ssDNA libraries of enrichment are collected, and entrusts the gloomy promise biotechnology share of the upper Shanghai's style limited Company is analyzed using high throughput sequencing technologies to library sequence, and analysis process is:PCR expands enriched library, and plus survey Sequence joint and Index parts;Purified library is selected by gel electrophoresis;Passed through using Agilent 2100Bioanalyzer Agilent High Sensitivity DNA Kit are to library Quality Control;Using Quant-iT PicogGreen dsDNA Assay Kit are carried out quantitatively to library;Using the platforms of IlluminateNextSeq 500, by template of single-stranded library bridge is carried out The amplification of formula PCR, sequencing primer are annealed, are sequenced in synthesis;And sequencing result is compared and analysis is enriched with.
(2) using the analysis of the UNAFold network platforms at 25 DEG C, 100mM Na+, 1mM Mg2+Under conditions of, aptamer The secondary structure of C203 sequences.The secondary structure schematic diagram for analyzing aptamer C203 sequences is as shown in Figure 1.
Embodiment three:The specificity analysis of aptamer C203:
(1) the aptamer C203 of iii vitro chemical synthesis FAM marks, and be dissolved in selecting buffer solution.
(2) with reference to step (2) in embodiment one, by BSA, staphylococcus aureus toxin A, staphylococcus aureus intestines Toxin B and Staphylococcal enterotoxin C1 couple respectively preparation BSA magnetic beads, staphylococcus aureus intestines with carboxyl magnetic bead Toxin A magnetic beads, SEB magnetic bead, Staphylococcal enterotoxin C1 magnetic bead and golden yellow grape Coccus Enteromycin C 2 magnetic bead.Wherein, the BSA is purchased from Sigma companies, the staphylococcus aureus toxin A, golden yellow Portugal Grape coccus enterotoxin B and Staphylococcal enterotoxin C1 are purchased from Toxin Technology companies of the U.S..
(3) take aptamer C203 solution obtained by 200 μ L steps (1) respectively with BSA magnetic beads obtained in step (2), Staphylococcus aureus toxin A magnetic bead, SEB magnetic bead, Staphylococcal enterotoxin C1 magnetic Pearl and staphylococcus aureus enterotoxin C 2 magnetic bead mix, and 1h is incubated at room temperature in magazine, if blank magnetic bead is control.
(4) the above-mentioned magnetic bead 3 times of Jing steps (3) is washed with 0.1%PBST, the aptamer combined with above-mentioned magnetic bead, 100 DEG C of buffer solution is selected to boil 5min wash-outs with 200 μ L.
(5) determine the fluorescence intensity of initial soln and eluent respectively using fluorescent quantitation instrument, calculate fluorescence Percentage bound= (initial fluorescent intensity-wash-out fluorescence intensity)/initial fluorescent intensity × 100%, with calculated value aptamer is tentatively represented The Percentage bound of C203 and target molecule.
As shown in Fig. 2 aptamer C203 is all remarkably higher than it with the Percentage bound of staphylococcus aureus enterotoxin C 2 With BSA, staphylococcus aureus toxin A, SEB, Staphylococcal enterotoxin C1 knot Conjunction rate, shows that aptamer C203 and the combination of staphylococcus aureus enterotoxin C 2 have preferably specificity.
Example IV:The affinity analysis of aptamer C203
(1) take the FAM labeling nucleic acid aptamers C203 solution of variable concentrations respectively with staphylococcus aureus enterotoxin C 2 Magnetic bead mixes, and 1h is incubated at room temperature in magazine.
(2) with reference to the step (4) and step (5) in embodiment three, experiment obtains and calculates variable concentrations aptamer The fluorescence Percentage bound of C203 solution and staphylococcus aureus enterotoxin C 2 magnetic bead.
(3) using the calculated value of fluorescence Percentage bound, draw aptamer C203 and combine Staphylococcus aureus enterotoxin The saturation binding curve of C2, calculates aptamer C203 and combines Staphylococcus aureus enterotoxin by nonlinear regression analysis The dissociation constant of C2.
As shown in figure 3, we obtain the saturation binding curve of aptamer C203, aptamer C203 is computed Dissociation constant be 3.05 ± 0.89nM, show the combination that aptamer C203 and staphylococcus aureus enterotoxin C 2 are combined Ability is strong, and dissociation constant is in nanomole rank.
Embodiment five:Aptamer C203 suppresses the superantigen activity of staphylococcus aureus enterotoxin C 2
(1) aseptic aspiration healthy adult volunteer peripheral blood, is diluted after anticoagulant heparin with equivalent RPMI1640 nutrient solution, is put On lymphocyte separation medium, acquisition human peripheral is separated using Conventional density gradients centrifugal process (2000rmp, 20min) single Nucleus (PBMCs).
(2) with the adjustment cell concentration of the RPMI1640 nutrient solutions containing 5% NBCS (NBS) and 5% Human autologous serum For 1~2 × 106/ mL, spreads 96 orifice plates, per the μ L of hole 100.
(3) each group adds the concentration of aptamer C203 to be followed successively by 0 μM, 10 μM respectively, adds per hole final concentration of The staphylococcus aureus enterotoxin C 2 of 250ng/mL, setting is not added with staphylococcus aureus enterotoxin C 2, is also not added with nucleic acid The blank control group of aptamers C203.
(4) cell is placed in into 37 DEG C, 5%CO2CO2Cultivate in incubator, after culture 24h, the CCK- of 10 μ L is added per hole 8, continue to cultivate 4h.
(5) absorbance (OD) of the every hole of spectrophotometer detection in 450nm.
As shown in figure 4, concentration of the abscissa for aptamer C203, ordinate is the OD values at 450nm.When nucleic acid is fitted When part C203 is 10 μM, staphylococcus aureus enterotoxin C 2 stimulates the proliferation water dawn of PBMCs aobvious reduction (P < 0.05), The above results show that aptamer C203 has in testing in vitro to the superantigen activity of staphylococcus aureus enterotoxin C 2 There is significantly inhibitory action, be a kind of potential staphylococcus aureus enterotoxin C 2 inhibitor.
SEQUENCE LISTING
<110>Fuzhou General Hospital, Nanjing Military Area, PLA
<120>The aptamer C203 of staphylococcus aureus enterotoxin C 2 and its screening technique and application
<160> 3
<210> 1
<211> 71
<212> DNA
<213>Artificial sequence
<400> 1
agggccgagc tcacttgtca ggtcgcctct tgcgcggcgc 40
acgggcggaa acgccgccgg cacaattgtg c 71
<210> 2
<211> 18
<212> DNA
<213>Artificial sequence
<400> 2
agggccgagc tcacttgt 18
<210> 3
<211> 18
<212> DNA
<213>Artificial sequence
<400> 3
gcacaattgt gccggcgg 18

Claims (10)

1. the aptamer C203 of a kind of staphylococcus aureus enterotoxin C 2, it is characterised in that:Its sequence is as follows:
AGGGCCGAGCTCACTTGTCAGGTCGCCTCTTGCGCGGCGC 40
ACGGGCGGAAACGCCGCCGGCACAATTGTGC 71
2. the aptamer C203 of staphylococcus aureus enterotoxin C 2 according to claim 1, it is characterised in that: 25 DEG C, 100mM Na+, 1mM Mg2+Under conditions of, its space structure is as follows:
3. the aptamer C203 of staphylococcus aureus enterotoxin C 2 according to claim 1, it is characterised in that:It is right 5 ' the ends or 3 ' ends of the aptamer C203 carry out FITC, amino, biotin, digoxin chemical modification.
4. the aptamer C203 of staphylococcus aureus enterotoxin C 2 according to claim 1, it is characterised in that:It is right The aptamer C203 truncate extend or number of base replace structure of modification obtained by product carry out FITC, ammonia Base, biotin, digoxin chemical modification.
5. the sieve of the aptamer C203 of the staphylococcus aureus enterotoxin C 2 according to claim 1-4 any one Choosing method, it is characterised in that:Based on the external SELEX triage techniqueses of aptamer, by the use of carboxyl magnetic bead as solid-phase media, With staphylococcus aureus enterotoxin C 2 as target, sieved from ssDNA libraries by staphylococcus aureus enterotoxin C 2 magnetic bead Choosing obtains the aptamer with staphylococcus aureus enterotoxin C 2 specific binding.
6. the screening technique of the aptamer C203 of staphylococcus aureus enterotoxin C 2 according to claim 5, its It is characterised by:It is comprised the following steps:
(1) preparation in library is screened:Prepare the ssDNA pool shown in following sequence:
5’-AGGGCCGAGCTCACTTGT-N35-CCGCCGGCACAATTGTGC-3’;
(2) staphylococcus aureus enterotoxin C 2 and carboxyl magnetic bead coupling are prepared into staphylococcus aureus enterotoxin C 2 magnetic bead;
(3) ssDNA libraries are carried out into hot activation process;
(4) the ssDNA libraries Jing after step (3) are carried out with the staphylococcus aureus enterotoxin C 2 magnetic bead obtained by step (2) Incubation;
(5) staphylococcus aureus enterotoxin C 2 magnetic bead of the Magnetic Isolation Jing after step (4), washes away staphylococcus aureus intestines poison Plain C2 magnetic bead surfaces are uncombined, the ssDNA of weak binding and non-specific binding;Heating staphylococcus aureus enterotoxin C 2 magnetic Pearl, collects the ssDNA with the specific binding of staphylococcus aureus enterotoxin C 2 magnetic bead, i.e. ssDNA enriched libraries;
(6) PCR amplifications:SsDNA enriched libraries obtained by step (5) are entered into performing PCR amplification, wherein PCR amplifications primer used For:
Primer P1:5’-FAM-AGGGCCGAGCTCACTTGT-3’
Primer P2:5’-Biotin-GCACAATTGTGCCGGCGG-3’;
(7) purifying of PCR primer:PCR primer is purified using small fragment purification kit;By dsDNA after purification with Streptavidin MagneSphere is incubated, scrubbed with reference to the Streptavidin MagneSphere of dsDNA, after dsDNA unwinds, with magnetic frame point From collection supernatant;Supernatant obtains the secondary ssDNA libraries for next round screening Jing after ethanol precipitation;
(8) Cycle Screening:By the secondary ssDNA libraries obtained by step (7), as the secondary library of next round screening, and repeat The screening process of step (3)~(7).
7. the aptamer C203 of the staphylococcus aureus enterotoxin C 2 according to claim 1-6 any one should With, it is characterised in that:Application in separation, purifying staphylococcus aureus enterotoxin C 2.
8. the aptamer C203 of the staphylococcus aureus enterotoxin C 2 according to claim 1-6 any one should With, it is characterised in that:Non-diseases methods for diagnosis and treatment application in analysis detection staphylococcus aureus enterotoxin C 2.
9. the aptamer C203 of the staphylococcus aureus enterotoxin C 2 according to claim 1-6 any one should With, it is characterised in that:It is the application in the targeted therapy of effector molecule in staphylococcus aureus enterotoxin C 2.
10. the aptamer C203 of the staphylococcus aureus enterotoxin C 2 according to claim 1-6 any one Using, it is characterised in that:Draw in treatment infection of staphylococcus aureus and in treatment staphylococcus aureus enterotoxin C 2 Play the application in related syndrome.
CN201611170849.9A 2016-12-16 2016-12-16 The aptamer C203 and its screening technique of staphylococcus aureus enterotoxin C 2 and application Active CN106636105B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611170849.9A CN106636105B (en) 2016-12-16 2016-12-16 The aptamer C203 and its screening technique of staphylococcus aureus enterotoxin C 2 and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611170849.9A CN106636105B (en) 2016-12-16 2016-12-16 The aptamer C203 and its screening technique of staphylococcus aureus enterotoxin C 2 and application

Publications (2)

Publication Number Publication Date
CN106636105A true CN106636105A (en) 2017-05-10
CN106636105B CN106636105B (en) 2019-01-22

Family

ID=58823295

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611170849.9A Active CN106636105B (en) 2016-12-16 2016-12-16 The aptamer C203 and its screening technique of staphylococcus aureus enterotoxin C 2 and application

Country Status (1)

Country Link
CN (1) CN106636105B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114634934A (en) * 2020-12-16 2022-06-17 中国人民解放军军事科学院军事医学研究院 Sequence of aptamer 3-2 and 2-27 for specifically recognizing staphylococcus aureus enterotoxin B and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257864A1 (en) * 2002-10-02 2006-11-16 Hau-Yang Tsen Primers useful in polymerase chain reaction for the identification of subtypes c1, c2 and c3 of staphylococcal enterotoxin type c
CN102633867A (en) * 2011-02-15 2012-08-15 中国科学院沈阳应用生态研究所 Antigenically-changed enterotoxin C2 mutant, coding gene thereof, preparation thereof and application thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257864A1 (en) * 2002-10-02 2006-11-16 Hau-Yang Tsen Primers useful in polymerase chain reaction for the identification of subtypes c1, c2 and c3 of staphylococcal enterotoxin type c
CN102633867A (en) * 2011-02-15 2012-08-15 中国科学院沈阳应用生态研究所 Antigenically-changed enterotoxin C2 mutant, coding gene thereof, preparation thereof and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ZHAO WB等: "Transcytosis, Antitumor Activity and Toxicity of Staphylococcal Enterotoxin C2 as an Oral Administration Protein Drug", 《TOXINS》 *
江丽等: "用SELEX技术筛选葡萄球菌肠毒素B特异性适配体", 《临床检验杂志》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114634934A (en) * 2020-12-16 2022-06-17 中国人民解放军军事科学院军事医学研究院 Sequence of aptamer 3-2 and 2-27 for specifically recognizing staphylococcus aureus enterotoxin B and application thereof
CN114634934B (en) * 2020-12-16 2024-04-26 中国人民解放军军事科学院军事医学研究院 Sequence of aptamer 3-2 and 2-27 for specifically recognizing staphylococcus aureus enterotoxin B and application thereof

Also Published As

Publication number Publication date
CN106636105B (en) 2019-01-22

Similar Documents

Publication Publication Date Title
CN113151282B (en) Aptamer binding to novel coronavirus (SARS-CoV-2) nucleocapsid protein and use thereof
CN102703454B (en) Nucleic acid aptamer capable of detecting myohemoglobin, microfluidic chip for screening and screening method and application
CN103732748A (en) Production method for nucleic acid aptamer
CN113481204B (en) Aptamer of protein, derivative and application thereof
CN106591315B (en) The aptamer C202 and its screening technique of staphylococcus aureus enterotoxin C 2 and application
KR100961532B1 (en) twenty one Single-stranded DNA aptamers having high affinity to tetracycline and it&#39;s analogues with high specificity and production method thereof
CN106701768B (en) The aptamer C201 and its screening technique of staphylococcus aureus enterotoxin C 2 and application
CN106636105B (en) The aptamer C203 and its screening technique of staphylococcus aureus enterotoxin C 2 and application
CN105349544A (en) Nucleic acid aptamer S3 of Staphylococcus aureus enterotoxin A and application thereof
CN106957905A (en) A kind of molecular detecting method and Primer composition and kit for being used to assess immunotherapy of tumors effect
KR20180052991A (en) DNA Aptamer Specifically Binding to Surface of Living Cell of Salmonella typhimurium and Uses Thereof
CN106854649B (en) The aptamer C204 and its screening technique of staphylococcus aureus enterotoxin C 2 and application
CN106801059B (en) The aptamer C205 and its screening technique of staphylococcus aureus enterotoxin C 2 and application
CN110819632B (en) Aptamer for binding to trastuzumab
CN104774923B (en) A kind of method for determining transcription control complex
CN105483133A (en) Staphylococcus aureus toxic shock syndrome toxin-1(TSST-1) aptamer T-7 and preparation method and application thereof
CN110885829B (en) Diphtheria toxin aptamer DT05 and application thereof
CN106866821A (en) A kind of method that utilization high throughput sequencing technologies quickly obtain nano antibody
CN110904112B (en) Diphtheria toxin aptamer DT03 and application thereof
CN106480042A (en) A kind of quick identification insulin aptamer INS2 and preparation method thereof
CN110885828B (en) Diphtheria toxin aptamer DT01 and application thereof
CN102766632A (en) Golgi apparatus membrane protein GP73 nucleic acid aptamer, as well as preparation method and application thereof
CN110951744B (en) Aptamer specifically binding tumor necrosis factor-alpha and application thereof
CN110923239A (en) Aptamer DT04 of diphtheria toxin and application thereof
CN110938631A (en) Aptamer DT02 of diphtheria toxin and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant